DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Topical Hydromorphone for Wound Healing

Information source: University of Minnesota
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Wound Healing

Intervention: hydromorphone (Drug)

Phase: Phase 1/Phase 2

Status: Terminated

Sponsored by: Hordinsky, Maria K., MD

Official(s) and/or principal investigator(s):
Maria Hordinsky, MD, Principal Investigator, Affiliation: University of Minnesota
Robert Hebbel, MD, Principal Investigator, Affiliation: University of Minnesota

Summary

The hypothesis is that topical opioids will hasten wound healing in humans.

Clinical Details

Official title: Topical Hydromorphone for Wound Healing

Study design: Treatment, Randomized, Single Blind, Placebo Control, Single Group Assignment, Efficacy Study

Primary outcome: Healing rates and microvessel density will be compared statistically for the control-ointment versus hydromorphone-ointment subjects.

Detailed description: This is based on our published data that morphine is a powerful stimulant of angiogenesis and our preclinical study of wounds in rats which demonstrate that topical opioids (morphine, hydromorphone and fentanyl) hasten healing of punch biopsy wounds. This study will focus on hydromorphone which was more powerful than morphine as a wound-healer in the rat study.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Self-identified as normal, healthy volunteers age 18-65.

Exclusion Criteria:

- Known bleeding disorder.

Locations and Contacts

Additional Information

Starting date: October 2003
Ending date: May 2007
Last updated: February 6, 2008

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014